Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Clinical trials and drug promotion: Selective reporting of study 329|
|Citation:||The International Journal of Risk and Safety in Medicine, 2008; 20(1-2):73-81|
|Jon N. Jureidini, Leemon B. McHenry, Peter R. Mansfield|
|Abstract:||Selective reporting is prevalent in the medical literature, particularly in industry-sponsored research. In this paper, we expose selective reporting that is not evident without access to internal company documents. The published report of study 329 of paroxetine in adolescents sponsored by GlaxoSmithKline claims that “paroxetine is generally well tolerated and effective for major depression in adolescents”. By contrast, documents obtained during litigation reveal that study 329 was negative for efficacy on all 8 protocol specified outcomes and positive for harm.|
|Keywords:||selective reporting; SSRI; litigation; industry sponsorship|
|Appears in Collections:||Paediatrics publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.